AHA Cardiorenal Protection

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease

Chronic kidney disease (CKD) with type 2 diabetes (T2D) is a major public health problem, resulting in significant cardiovascular and kidney adverse outcomes worldwide. Despite the widespread use of standard-of-care therapies for CKD with T2D over the past few decades, rates of progression to end-stage kidney disease remain high with no beneficial impact on its accompanying burden of cardiovascular disease.

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and the EASD

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommenda- tions. 

View the PDF

ADA Standards of Care and ACC/AHA Guidelines: Best Practices and Recommendations for CVD Prevention in Patients with T2D

ADA Standards of Care and ACC/AHA Guidelines: Best Practices and Recommendations for CVD Prevention in Patients with T2D
ADA Standards of Care and ACC/AHA Guidelines: Best Practices and Recommendations for CVD Prevention in Patients with T2D

Lifestyle modifications should be implemented as needed to manage weight and to incorporate dietary adjustments.

View the PDF

The American Diabetes Association’s Standards of Care in Diabetes—2024

Watch the Know Diabetes by Heart™ presentation on the Standards of Care in Diabetes—2024 (Standards of Care) from the American Diabetes Association® (ADA). Dennis Bruemmer, MD, PhD, highlights important updates to this year’s Standards of Care and how those changes impact clinical care, especially as they relate to type 2 diabetes, cardiovascular disease (CVD), and chronic kidney disease (CKD).

Date: Friday, January 26, 2024
Time: 1:30 pm – 2:30 pm ET

 

Dennis Bruemmer, MD, PhD

Dennis Bruemmer, MD, PhD, Cleveland Clinic

Robert A. Gabbay, MD, PhD, Chief Scientific and Medical Officer, American Diabetes Association

American Heart Association’s Scientific Sessions Highlights: Latest Research on CVD and Diabetes

Date: Wednesday, November 29, 2023
Time: 4:00 pm – 5:00 pm ET

Watch Know Diabetes by Heart™ for an expert panel discussion on new science released at the American Heart Association’s Scientific Sessions. Panelists will discuss clinical highlights from the 2023 Scientific Sessions related to cardiovascular disease risk management in patients with diabetes, including renal disease. As experts in their field, they will also relate how new findings can be incorporated into clinical practice and how to apply clinically relevant highlights to improve patient outcomes.

Discussion topics include: 

  • Late-Breaking Science: In Depth with SELECT Trial
  • Diabetes and Heart Failure: New Mechanistic Insights and Therapeutics Strategies
  • Navigating the Intersection of Cardiovascular, Kidney and Metabolic Health
  • Cardiovascular-kidney-metabolic Syndrome Pathophysiology and Therapies

Learning objectives:  

  • Identify clinical highlights from the 2023 American Heart Association’s Scientific Sessions related to cardiovascular disease risk management in patients with type 2 diabetes.
  • Relate how new findings can be incorporated into clinical practice.
  • Apply clinically relevant highlights to improve patient outcomes.

Dr. Justin Echouffo Tcheugui, MD, PhD; Johns Hopkins University

Dr. Justin Echouffo Tcheugui, MD, PhD; Johns Hopkins University

Dr. Sadiya Khan, MD, MSc; Northwestern Medicine

Dr. Sadiya Khan, MD, MSc; Northwestern Medicine

Dr. Tiffany Powell-Wiley, MD, MPH; National Institutes of Health

Dr. Tiffany Powell-Wiley, MD, MPH; National Institutes of Health

2023 Episode 9 – New Science from AHA Scientific Sessions 2022 – CVD Risk Management in Patients with T2D

This podcast highlights the new science presented at the American Heart Association’s (AHA’s) Scientific Sessions in 2022. Jane Reusch, MD, Nathan Wong, PhD, MPH, and Chiadi Ndumele, MD, PhD, MHS discuss clinical highlights related to CVD risk management in patients with diabetes, including renal disease, and how to incorporate these findings into clinical practice.

Play the podcast in Apple Podcasts.

podcast player graphic

2023 Episode 9 – New Science from AHA Scientific Sessions 2022 – CVD Risk Management in Patients with T2D

KDBH Podcast – 2022 AHA New Science – Transcript

Jane E.B. Reusch, MD, FAHA, is Professor of Medicine, Bioengineering, and Integrative Physiology, and Associate Director of the Center for Women’s Health Research, Anschutz Medical Campus at the University of Colorado; Staff Physician and Merit Review Investigator at the Rocky Mountain Regional VAMC.  As a physician-scientist, Dr. Reusch has made fundamental contributions to our understanding of cellular metabolism of diabetes and its complications studying people with diabetes and cell and animal models. She has been elected to the American Society for Clinical Investigation and the American Association of Physicians, and awarded the Women of Valor in Diabetes Award, The Endocrine Society Laureate Award for Mentoring and the Banting Medal for Leadership and Service and Albert Renold Award from the American Diabetes Association. She served as President for Medicine and Science of the American Diabetes Association and on the ADA professional Practice Committee 2019-2021 (writing group for the ADA Standard of Medical Care for Diabetes).

Jane Reusch

Jane E. B. Reusch, MD, FAHA (Center for Women’s Health Research, Anschutz Medical Campus at the University of Colorado; Staff Physician and Merit Review Investigator at the Rocky Mountain Regional VAMC)

Nathan D. Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC , is a cardiovascular epidemiologist and specialist in preventive cardiology. His primary research interests include subclinical atherosclerosis and epidemiology and management of dyslipidemia and diabetes in relation to cardiovascular disease.  Past/current investigator with numerous NIH observational studies on cardiovascular disease and clinical trials of lipid-lowering. Dr. Wong has authored over 400 papers and co-edited seven textbooks and is currently president of the InterAmerican Heart Foundation and past president of the American Society for Preventive Cardiology and Pacific Lipid Association Chapter of the NLA.

Nathan Wong

Nathan Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC (Professor of Medicine and Director, Heart Disease Prevention Program, University of California, Irvine)

Chiadi Ndumele, MD, PhD, MHS, is Director of Obesity and Cardiometabolic Research for Johns Hopkins Cardiology. Dr. Ndumele is the Immediate Past Chair of the Obesity Committee of the American Heart Association (AHA), and current Vice-Chair of the AHA’s Lifestyle and Cardiometabolic Health Council. His research focuses on the impact of obesity and cardiometabolic risk factors on the development of cardiovascular disease, particularly heart failure, and strategies for heart failure prevention.

Chiadi Ndumele, MD, PhD, MHS

Chiadi Ndumele, MD, PhD, MHS (Assistant Professor of Medicine, Johns Hopkins University School of Medicine)

American Diabetes Association’s Standards of Care in Diabetes—2023

Date: Wednesday, February 8, 2023
Time: 2:00 pm ET

Join Know Diabetes by Heart™ for a presentation on the Standards of Care in Diabetes—2023 (Standards of Care) from the American Diabetes Association® (ADA). Dr. Dennis Bruemmer and Dr. Alexander Chang will highlight important updates to this year’s Standards of Care and how those changes impact clinical care, especially as they relate to type 2 diabetes, cardiovascular disease, and chronic kidney disease.

Learning Objective

Identify the ADA’s 2023 Standards of Care for classifying, diagnosing, preventing, and treating diabetes, cardiovascular disease, and chronic kidney disease.

 

Dennis Bruemmer, MD, PhD

Dennis Bruemmer, MD, PhD, Cleveland Clinic

Alexander Chang, MD, MS

Alexander Chang, MD, MS, Geisinger Health

AHA Scientific Sessions Highlights—Latest Research on CVD and Diabetes

Join Know Diabetes by HeartTM for an expert panel discussion on new science released at the American Heart Association’s Scientific Sessions. Panelists will discuss clinical highlights from the 2022 Scientific Sessions related to cardiovascular disease risk management in patients with diabetes, including renal disease. As experts in their field, they will also relate how new findings can be incorporated into clinical practice and how to apply clinically relevant highlights to improve patient outcomes.

Date: Monday, December 5, 2022
Time: 1:00 pm ET

Learning Objectives:

  • Identify clinical highlights from the 2022 AHA Scientific Sessions related to cardiovascular disease risk management in patients with type 2 diabetes.
  • Relate how new findings can be incorporated into clinical practice.
  • Apply clinically relevant highlights to improve patient outcomes.

Chiadi Ndumele, MD, PhD, MHS

Chiadi Ndumele, MD, PhD, MHS (Assistant Professor of Medicine, Johns Hopkins University School of Medicine)

Jane Reusch, MD

Jane Reusch, MD (Professor of Medicine, Bioengineering and Biochemistry, Associate Director of the Ludeman Family Center for Women’s Health Research at the University of Colorado Anschutz Medical Campus)

Nathan Wong

Nathan Wong, PhD, MPH, FACC, FAHA, FNLA, FASPC (Professor of Medicine and Director, Heart Disease Prevention Program, University of California, Irvine)

American Diabetes Association 82nd Scientific Sessions Recap–Latest Research on CVD and Diabetes including Renal Risk Management

Join Know Diabetes by Heart for an expert panel discussion on new science released at the 82nd American Diabetes Association’s Scientific Sessions. Panelists will discuss clinical highlights from the 2022 Scientific Sessions related to cardiovascular disease and renal risk management and how to apply these relevant highlights to improve patient outcomes.

Date: Monday, June 27, 2022
Time: 4:00 pm – 5:00 pm ET

Learning Objectives:

At the end of this activity, you will be able to:

  • Recall clinical highlights from the 2022 Scientific Sessions related to cardiovascular disease and renal risk management.
  • Identify applications of new findings to clinical practice that can improve patient outcomes.

Sanjay Kaul

Sanjay Kaul, MD, FACC, FAHA (Professor of Medicine, Cedars-Sinai Medical Center)

Neda Rasouli

Neda Rasouli, MD (Professor of Medicine, University of Colorado)

2022 American Diabetes Association Standards of Care

Join Know Diabetes by Heart™ for a presentation on the Standards of Medical Care in Diabetes—2022 (Standards of Care) from the American Diabetes Association® (ADA).

Date: Wednesday, February 2, 2022
Time: 4:00 pm – 5:00 pm ET

Join Know Diabetes by Heart™ for a presentation on the Standards of Medical Care in Diabetes—2022 (Standards of Care) from the American Diabetes Association® (ADA). Dr. Nuha El Sayed will highlight important updates to this year’s Standards of Care and how those changes impact clinical care, especially as they related to type 2 diabetes and cardiovascular disease.

Learning Objectives:

  • Identify the ADA’s 2022 Standards of Care for classifying, diagnosing, and treating diabetes and cardiovascular disease.

Nuha Ali El Sayed, MD, MM Sc., Vice President, American Diabetes Association and Instructor in Medicine, Harvard Medical School